Portage Biotech (NASDAQ:ATON) Trading Up 0.9% – Should You Buy?

Shares of Portage Biotech Inc. (NASDAQ:ATON) rose 0.9% during mid-day trading on Tuesday . The company traded as high as $0.3688 and last traded at $0.3630. Approximately 357,732 shares changed hands during trading, a decline of 37% from the average daily volume of 564,833 shares. The stock had previously closed at $0.3599.

Analysts Set New Price Targets

A number of research firms recently commented on ATON. HC Wainwright initiated coverage on shares of Portage Biotech in a research note on Tuesday, February 24th. They issued a “buy” rating and a $2.00 price objective for the company. Weiss Ratings initiated coverage on shares of Portage Biotech in a research note on Monday, January 26th. They set a “sell (e+)” rating on the stock. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Portage Biotech presently has an average rating of “Hold” and an average price target of $2.00.

Portage Biotech Stock Performance

The stock has a market cap of $8.51 million, a P/E ratio of -0.04 and a beta of 0.38.

Portage Biotech (NASDAQ:ATON) last released its earnings results on Wednesday, January 21st. The company reported ($4.13) earnings per share (EPS) for the quarter.

Portage Biotech Company Profile

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.